Corvus misses EPS but beats revenue estimates, cash runway into Q2 2028
Corvus Pharmaceuticals reports Q1 2026 non-GAAP EPS -$0.15 (-15% YoY) on revenue $0, misses EPS but beats revenue estimates
- Q1 2026 net loss totaled $13.7M, with no revenue reported in the quarter.
- Ended Q1 2026 with $236.7M in cash, providing runway into Q2 2028.
- Advanced soquelitinib into Phase 2 trial for atopic dermatitis during the quarter.
- Plans additional Phase 2 soquelitinib studies in hidradenitis suppurativa and asthma following atopic dermatitis trial initiation.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.